About 8 results found for searched term "ATR-IN-21" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41409 | ATR-IN-21 | ATM/ATR |
| ATR-IN-21 is a potent ATR inhibitor with an IC50 value of <1000 nM. | ||
| M4796 | Veratramine | Others |
| NSC17821; NSC23880 | ||
| Veratramine(NSC17821; NSC23880) is a signal transduction inhibitor that acts on tumors. | ||
| M10594 | PF-07321332 (Nirmatrelvir) | Anti-infection |
| Nirmatrelvir; PF07321332; PF-7321332 | ||
| PF-07321332 (Nirmatrelvir) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme. | ||
| M11022 | DMU-212 | ERK |
| DMU-212 is a resveratrol methylated derivative with anti-division, antiproliferative, antioxidant and apoptosis-promoting activities. DMU-212 causes mitosis to stop by inducing apoptosis and activating the ERK1/2 protein. | ||
| M21188 | NBI-921352 | Sodium Channel |
| Zandatrigine；XEN901 | ||
| Zandatrigine (NBI-921352) is a sodium channel protein type 8 subunit alpha blocker. | ||
| M28938 | SRI 31215 TFA | c-Met |
| SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer. | ||
| M29715 | VD2173 | Serine/Threonine Protease |
| VD2173 is a side chain cyclized macrocyclic peptide inhibitor of HGF-activating serine proteases. VD2173 potently inhibits matriptase and hepsin. VD2173 can be used for the research of lung cancer. | ||
| M30933 | Levobetaxolol | Adrenergic Receptor |
| (S)-Betaxolol | ||
| Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
